SGX523 has shown significant selectivity for the cMET receptor tyrosine kinase over more than 200 protein kinases and has demonstrated both potent in vitro blockade of the activity of this cancer target and in vivo activity against human cancer cells that depend on cMET for their uncontrolled growth and proliferation.
The company expects to begin Phase I clinical trials of SGX523 for solid tumor cancer patients in early 2008.
Mike Grey, president and CEO of SGX Pharmaceuticals, said: “We look forward to capitalizing on this positive momentum and initiating clinical studies in solid tumor cancer patients following FDA review of our submission.”